WO2008143880A8 - Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales - Google Patents

Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales Download PDF

Info

Publication number
WO2008143880A8
WO2008143880A8 PCT/US2008/006158 US2008006158W WO2008143880A8 WO 2008143880 A8 WO2008143880 A8 WO 2008143880A8 US 2008006158 W US2008006158 W US 2008006158W WO 2008143880 A8 WO2008143880 A8 WO 2008143880A8
Authority
WO
WIPO (PCT)
Prior art keywords
brain injury
traumatic brain
bryologs
bryostatins
therapeutic effects
Prior art date
Application number
PCT/US2008/006158
Other languages
English (en)
Other versions
WO2008143880A2 (fr
WO2008143880A3 (fr
Inventor
Ofer Zohar
Daniel L Alkon
Original Assignee
Brni Neurosciences Inst
Ofer Zohar
Daniel L Alkon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/068,742 external-priority patent/US9974832B2/en
Application filed by Brni Neurosciences Inst, Ofer Zohar, Daniel L Alkon filed Critical Brni Neurosciences Inst
Publication of WO2008143880A2 publication Critical patent/WO2008143880A2/fr
Publication of WO2008143880A3 publication Critical patent/WO2008143880A3/fr
Publication of WO2008143880A8 publication Critical patent/WO2008143880A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte: sur l'utilisation de protéines kinases activant ou renforçant le facteur de croissance des nerf (NGF); sur le facteur tiré du cerveau (BDNF); sur d'autres facteurs neurotropes traitant les lésions traumatiques cérébrales (TBI), et spécifiquement, sur des méthodes de traitement des lésions traumatiques cérébrales comprenant les étapes suivantes: identification d'un sujet ayant subi une lésion traumatique cérébrale; administration au sujet d'une quantité efficace d'une préparation pharmaceutique comprenant un activateur de la protéine kinase C (PKC) ou de l'acide 4-méthylcatéchol acétique, dans un excipient ad hoc pour traiter au moins un symptôme de lésion traumatique cérébrale
PCT/US2008/006158 2007-05-24 2008-05-14 Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales WO2008143880A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92466207P 2007-05-24 2007-05-24
US60/924,662 2007-05-24
USPCT/US2008/001755 2008-02-11
US12/068,742 US9974832B2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
PCT/US2008/001755 WO2008100449A2 (fr) 2007-02-09 2008-02-11 Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales
US12/068,742 2008-02-11

Publications (3)

Publication Number Publication Date
WO2008143880A2 WO2008143880A2 (fr) 2008-11-27
WO2008143880A3 WO2008143880A3 (fr) 2009-06-04
WO2008143880A8 true WO2008143880A8 (fr) 2009-08-13

Family

ID=40091420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006158 WO2008143880A2 (fr) 2007-05-24 2008-05-14 Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales

Country Status (1)

Country Link
WO (1) WO2008143880A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804789A1 (fr) 2010-07-08 2012-01-12 Daniel L. Alkon Activateurs de pkc et anticoagulant dans un regime pour le traitement d'un accident vasculaire cerebral
RU2470302C1 (ru) * 2011-09-21 2012-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования когнитивных нарушений в отдаленном периоде черепно-мозговой травмы
US20160025704A1 (en) * 2013-03-15 2016-01-28 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
WO2023133230A1 (fr) * 2022-01-08 2023-07-13 Sohn Joanna Monoacétyldiglycérides (plag) en tant qu'agent d'atténuation pour lésion cérébrale traumatique et lésion de reperfusion ischémique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
EP1551387A4 (fr) * 2002-07-02 2007-10-10 Brni Neurosciences Inst Activation de la pkc utilisee pour renforcer la secretion de la sapp-a et pour ameliorer la gognition, au moyen de composes du type bryostatine
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
CN101541322A (zh) * 2006-07-28 2009-09-23 布朗歇特洛克菲勒神经科学研究所 刺激细胞生长、突触重塑和巩固长期记忆的方法
EP3332797A3 (fr) * 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, bryologues et autres substances apparentées sur les troubles de la mémoire et les lésions cérébrales suite à un traumatisme crânien

Also Published As

Publication number Publication date
WO2008143880A2 (fr) 2008-11-27
WO2008143880A3 (fr) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2008100449A3 (fr) Effets thérapeutiques des bryostatines, de leurs analogues, et d'autres substances connexes sur l'affaiblissement de la mémoire induite par un traumatisme crânien et sur les lésions cérébrales
Kuric et al. Dopamine receptor activation increases glial cell line-derived neurotrophic factor in experimental stroke
ATE418991T1 (de) Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
WO2006034373A8 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
WO2006099015A3 (fr) Carotenoides, analogues de carotenoides ou derives de carotenoides permettant de traiter les troubles proliferatifs
EP1140840A4 (fr) Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
TW200621788A (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase Iε
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2007137247A3 (fr) Traitement de troubles dépressifs
WO2008143880A8 (fr) Effets thérapeutiques des bryostatines, bryologues, et autres substances associées sur des défaillances de mémoire dues ä à des traumatismes crâniens ou à des lésions traumatiques cérébrales
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
Nori et al. Increased nerve growth factor signaling in sensory neurons of early diabetic rats is corrected by electroacupuncture
WO2005089496A3 (fr) Procédés pour le traitement de synucléinopathies
WO2008100450A3 (fr) Effets thérapeutiques de bryostatines, de bryologues et d'autres substances apparentées sur l'altération de la mémoire induite par une ischémie/un accident vasculaire cérébral et une lésion cérébrale
Wanner et al. Muscarinic receptors within the ventromedial hypothalamic nuclei modulate metabolic rate during physical exercise
WO2003103573A3 (fr) Procedes de traitement d'un trouble neurologique par administration peripherique d'un facteur trophique
Miyazato et al. Locus coeruleus involvement in the effects of immobilization stress on the p13 midlatency auditory evoked potential in the rat
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
WO2008033754A3 (fr) Méthodes et compositions de traitement de la dépression vasculaire.
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
HUE033997T2 (en) Fluoro-9-methyl-beta-carbolines
IL194346A0 (en) Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application
BR0316029A (pt) Combinação
MXPA05004917A (es) Combinacion que comprende docetaxel y un inhibidor cdk.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08754450

Country of ref document: EP

Kind code of ref document: A2